| 201 |
23682812 | Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. | 2013 Jul-Aug |
3 |
| 202 |
23697602 | An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. | 2013 Jun |
1 |
| 203 |
23870999 | Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. | 2013 Dec 1 |
1 |
| 204 |
24101324 | A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. | 2013 Oct |
2 |
| 205 |
24155780 | Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. | 2013 |
2 |
| 206 |
24168763 | Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. | 2013 |
6 |
| 207 |
24223926 | An integrated model of the transcriptome of HER2-positive breast cancer. | 2013 |
1 |
| 208 |
21359953 | Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. | 2012 Apr |
1 |
| 209 |
21380780 | Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. | 2012 Jun |
1 |
| 210 |
21920731 | Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. | 2012 Sep |
1 |
| 211 |
22094934 | Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. | 2012 Apr |
2 |
| 212 |
22116711 | A new anticancer compound, oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through Bax activation. | 2012 Sep 15 |
1 |
| 213 |
22679488 | Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. | 2012 |
1 |
| 214 |
22687601 | Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. | 2012 Aug |
1 |
| 215 |
22772380 | Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. | 2012 Aug |
1 |
| 216 |
22824824 | Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance. | 2012 Sep |
1 |
| 217 |
22851567 | Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. | 2012 Sep 20 |
1 |
| 218 |
23028798 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. | 2012 |
1 |
| 219 |
23268070 | [A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel]. | 2012 Nov |
2 |
| 220 |
23422737 | Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. | 2012 Mar |
2 |
| 221 |
23960813 | The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). | 2012 Oct |
1 |
| 222 |
21086124 | In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. | 2011 Mar |
1 |
| 223 |
21350003 | A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. | 2011 May 15 |
1 |
| 224 |
21712253 | Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. | 2011 Aug |
2 |
| 225 |
21788566 | Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | 2011 Sep 1 |
1 |
| 226 |
21868556 | Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. | 2011 Sep |
1 |
| 227 |
21887460 | Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. | 2011 Dec |
1 |
| 228 |
22135629 | A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy. | 2011 Sep |
1 |
| 229 |
22173491 | Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation. | 2011 Dec |
2 |
| 230 |
19826412 | Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. | 2010 Jan 14 |
1 |
| 231 |
20095796 | Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. | 2010 Apr |
1 |
| 232 |
20145176 | Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. | 2010 Feb 15 |
1 |
| 233 |
20150272 | Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. | 2010 Mar |
3 |
| 234 |
20198351 | Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel. | 2010 Apr |
5 |
| 235 |
20218616 | Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. | 2010 Apr 28 |
1 |
| 236 |
20332474 | Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. | 2010 Feb |
1 |
| 237 |
20473628 | A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. | 2010 Dec |
2 |
| 238 |
20498641 | Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. | 2010 Jul 22 |
5 |
| 239 |
20530274 | Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. | 2010 Jul 10 |
1 |
| 240 |
20547325 | Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP. | 2010 Aug |
4 |
| 241 |
20664599 | Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. | 2010 Sep 7 |
6 |
| 242 |
20673976 | Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. | 2010 Oct |
1 |
| 243 |
20705560 | Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. | 2010 Aug 1 |
3 |
| 244 |
20975068 | Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. | 2010 Dec 1 |
1 |
| 245 |
21029701 | [Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer]. | 2010 Jul |
2 |
| 246 |
21088439 | A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. | 2010 |
2 |
| 247 |
21139994 | Digitoxin activates EGR1 and synergizes with paclitaxel on human breast cancer cells. | 2010 Nov 18 |
2 |
| 248 |
21160270 | [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. | 2010 Dec |
1 |
| 249 |
21188093 | Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. | 2010 Jan 7 |
1 |
| 250 |
18548321 | A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. | 2009 |
1 |